Hospital

Subgroup analyses suggest that a primary dose of the COVID-19 vaccine does not increase risk of herpes zoster infection, regardless of age, immunocompromised status, and type of vaccine administered.

Data from an updated systematic literature review show positive outcomes for both cervical and non-cervical disease in men and women.

Researchers also noted an increasing rate of seroconversion with COVID-19 booster vaccination series.

Melanie Galvin, PharmD, BCSCP, explains how Northwell Health implemented changes to bring the health system up-to-date with the revisions to USP chapters <797> and <800>.

Findings support the potential protective association of vaccination in reducing long COVID, although it does not appear to eliminate the risk.

Reemergence of pertussis continues despite high immunization rates.

Approximately 2 years after patients were infected with COVID-19, non-hospitalized patients suffered from post-COVID-19 symptoms nearly 8% more than hospitalized patients.

Pharmacists can coordinate educational programs for patients to normalize quality of life and minimize infusion-related pain.

Although long-term health issues from COVID-19 are a major public health concern, evidence on post-acute COVID-19 syndrome, or post-COVID-19, is still limited, specifically among children and adolescents.

Individuals with COVID-19 reinfections were twice as likely to die and three times more likely to be hospitalized than those who did not have COVID-19 multiple times.

New system combines computational and experimental techniques to map evolutionary cancer lineages in their natural habitat of human tissue.

Both of Moderna's bivalent boosters showed neutralizing activity against BQ.1.1, an increasingly dominant emerging variant, confirming that updated vaccines have the potential to offer protection as the virus continues to evolve.

Annie Lambert, PharmD, BCSCP, discusses how to approach the implementation of the revised USP chapter guidelines before the enforcement date in fall 2023.

Teplizumab-mzwv is administered through injection and can delay the onset of type 1 diabetes in adults and pediatric patients.

Brian Serumaga, PhD, of US Pharmacopeia (USP) discusses the revisions to compounding chapters <795> and <797> and the resources available to help pharmacists update their practices.

Bepirovirsen produced sustained clearance of hepatitis B virus and hepatitis B surface antigens.

Dapagliflozin is the first SGLT2 inhibitor approved by the FDA for treatment of patients with heart failure (NYHA class II-IV) with reduced ejection fraction.

Patients administered 75 mg or higher of olpasiran every 12 weeks had a 95% or greater reduction in Lp(a) compared to placebo at week 36.

The Elecsys NT-proBNP test is an objective biomarker that aids in the diagnosis of individuals believed to have congestive heart failure.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Ponatinib (Iclusig; Takeda) combined with reduced-intensity chemotherapy achieved higher minimal residual disease-negative complete remission rates in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia compared to imatinib.

Investigators find that despite the same quantity of respiratory syncytial virus and presentation, some of the samples demonstrated signs of greater damage to cells.

Complete due diligence before selecting a compounding pharmacy and establishing an outsourcing relationship.

Despite an apparent benefit of intravenous immunoglobulin (IVIG) on early discharge, the likelihood of needing second-line treatment was 3 times higher in patients who initiated treatment with IVIG alone.

Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products.

Analysis of central Missouri discovers differences in co-infection occurrence between Delta and Omicron variants.

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

cobas MPXV targets 2 different regions of the monkeypox virus genome that are less prone to mutations than other parts of the genome.